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We evaluated the effect of hyperandrogenism in ovaries with functional and regressing corpora lutea (CL) and the action of metformin in
preventing these possible alterations using a mouse model. To obtain a CL functional for 9G1 days, immature female mice of the BALB/c
strain were injected i.p. with 10 IU/mouse of pregnant mare’s serum gonadotropin (PMSG). DHEA (60 mg/kg body weight s.c., 24 and 48 h
prior to kill) decreased both serum progesterone (P) and estradiol (E2) levels and increased the activity of superoxide dismutase (SOD) from
ovaries with functional CL (on day 5 after PMSG). It increased P and E2 and the activities of SOD and catalase (CAT) and decreased
lipoperoxidation of ovaries with regressing CL (on day 9 after PMSG). Treatment with DHEA did not affect the production of prostaglandin
F2a (PGF2a) or PGE by ovaries with functional CL, whereas DHEA decreased PGF2a and increased PGE production by ovaries with
regressing CL. Metformin (50 mg/kg body weight, orally) given together with DHEA restored E2 levels from mice with ovaries with
functional CL and serum P, PGF2a and PGE levels, and oxidative balance in mice with ovaries with regressing CL. Metformin alone was able
to modulate serum P and E2 levels, lipoperoxidation, SOD and CAT, and the 5,5-dimethyl-1-pyrroline N-oxide/
%OH signal. These findings
suggest that hyperandrogenism is able to induce or to rescue CL from luteolysis and metformin treatment is able to prevent these effects.
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Luteolysis, or corpus luteum (CL) regression, a normal and
necessary event in the mammalian reproductive cycle, is
related to a decline in serum progesterone (P) production
(functional luteolysis) followed by morphological
changes and tissue remodeling events within the luteal
tissue (structural luteolysis) (McCracken et al. 1999). The
generation of reactive oxygen species (ROS), such as the
superoxide radical (O,K2 ), H2O2, and hydroxyl radical
(%OH), increases during functional luteolysis (Motta et al.
2001a, Minegishi et al. 2002). Accumulation of ROS is a
consequence of the uncontrolled lipid peroxidation
(LPO) of cellular membranes. The increased LPO leads
to the loss of gonadotropin receptors, a decreased
production of cAMP, and finally to the loss of luteal
function (Wang et al. 1991). Protection against oxidative
stress in cells is provided by enzymes (superoxide
dismutase (SOD), catalase (CAT), and glutathione per-
oxidase), metabolites (glutathione: GSH), or vitamins
(Agarwal et al. 2005). Enhanced LPO leads to the
accumulation of the radical superoxide (O,K2 ). SOD is
responsible for the elimination of cytotoxic active
oxygen; O,K2 by catalysing the dismutation of the super-
oxide radical to oxygen and H2O2. This is an important
step of the antioxidant cascade since the accumulation ofq 2009 Society for Reproduction and Fertility
ISSN 1470–1626 (paper) 1741–7899 (online)O,K2 leads to the formation of peroxynitrite, one of the
most aggressive ROS. The accumulation of H2O2 is
preventedbyCAT. This enzyme turnsH2O2 intowater and
oxygen. The accumulation ofH2O2 leads to the formation
of %OH, another aggressive radical. GSH is an antioxidant
metabolite involved in reactions of oxide reduction, thus
neutralizing oxidant species. It has been reported that
antioxidant defenses are regulated by hormones (Motta
& Gimeno 1997, Motta et al. 2001a, 2001b, Tam et al.
2003, Estevez et al. 2004, Duarte et al. 2005).
Prostaglandins (PGs) also regulate luteal function
(Wiltbank & Ottobre 2003). The mechanisms leading
to luteolysis are species specific and complex; never-
theless, PGs play an important role in its regulation. The
addition of PGE to cultured ovine (Weems et al. 1997),
bovine (Kotwica et al. 2006), human (Endo et al. 1988),
and rat luteal cells (Hurwitz et al. 2002) increases the
production of P. In contrast, the release of PGF2a initiates
luteal regression in domestic livestock (Knickerbocker
et al. 1988), pigs (Gadsby et al. 1990), bovines (Hansel
1996), mice (Sugimoto et al. 1997), and women
(Ristimaki et al. 1997). It has been well established that
PGF2a is responsible for the loss of luteal functions via
enhancing the production of ROS (Sawada & Carlson
1991, Sugino et al. 1996). However, the relationshipDOI: 10.1530/REP-08-0325
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Figure 1 (A) Serum progesterone levels from mice with ovaries with
functional corpora lutea treated with vehicle (control), metformin,
DHEA, and DHEACmetformin. (B) Serum estradiol levels from mice
with ovaries with functional corpora lutea treated with metformin,
DHEA, and DHEACmetformin. Each column represents the mean
GS.E.M. of ten measurements from different animals, *P!0.001.
572 V A Sander and othersbetween PGs and the response of the antioxidant
defenses in different systems is controversial (Sugino
et al. 2004, Al-Gubory et al. 2005, Garrel et al. 2007).
Polycystic ovary syndrome (PCOS) in women is
characterized by hyperandrogenemia, hirsutism, oligo-
or amenorrhea, and anovulation (Franks 1995, Asuncion
et al. 2000). The ovarian function of women with PCOS
is altered. It has been reported that hyperandrogenism
leads to abnormal length of estrus cycles and anovula-
tion in rats (Lee et al. 1991, 1998, Henmi et al. 2001) and
high rates of recurrent miscarriages in early pregnant
women with PCOS (Glueck et al. 2002). In previous
studies, we have reported that hyperandrogenization of
prepuberal BALB/c mice by treatment with DHEA
induces endocrine and immune disturbances in mouse
ovarian tissue (Luchetti et al. 2004, Sander et al. 2006)
and embryo resorption of early pregnant mice (Sander
et al. 2005, Solano et al. 2006). The first aim of the
present study was to assess the mechanisms by
which hyperandrogenization affects the lifespan of CL.
Particularly, we were interested in studying the impact
of an excess of androgens in the oxidant–antioxidant
balance and its relationship with the PG system.
Multiple concomitant therapies have been applied in
PCOS women to address the variety of symptoms and to
achieve better results. Recent studies have investigated
the role of a family of insulin-sensitizing agents: the
biguanides. Although the use of metformin (N,N 0-
dimethylbiguanide) is becoming accepted and wide-
spread, it has been clinically used without a complete
understanding of the mechanisms involved. Metformin
reduces insulin resistance (Fedorcsak et al. 2003,
Harbone et al. 2003, Lord et al. 2003), affects ovarian
steroidogenesis (La Marca et al. 2002, Mansfield et al.
2003, Elia et al. 2006, Sander et al. 2006, Tosca et al.
2006a), and restores ovulation of anovulatory women
with PCOS (Palomba et al. 2004, 2006). The treatment
with metformin is also able to improve uterine
vascularization in PCOS patients (Palomba et al. 2006).
In addition, metformin prevents early embryo resorption
in women with PCOS (Jakubowicz et al. 2004) by
regulating both the PG and NO systems (inducible and
constitutive nitric oxide synthase activity), the expression
of progesterone-induced blocking factor, and the
production of cytokines (Luchetti et al. 2008). Thus,
our second objective was to investigate the action of
metformin in preventing the ovarian dysfunctions
produced by hyperandrogenism.Results
Effect of hyperandrogenism and metformin on P and
estradiol levels
In mice with functional CL (day 5), the hyperandrogen-
ization with DHEA decreased both serum Pand estradiol
(E2) levels when compared to controls (Fig. 1A and BReproduction (2009) 138 571–579respectively). Metformin alone decreased serum Pand E2
levels and metformin administered together with DHEA
prevented the effect of DHEA on E2 levels, whereas the
levels of P remained lower than controls (Fig. 1A and B).
The hyperandrogenization with DHEA increased both
serum Pand E2 levels when compared to controls in mice
with ovaries with regressing CL (Fig. 2A and B
respectively). Metformin alone increased serum P and
E2 levels and metformin administered together with
DHEA prevented the effect of DHEA on serum P levels,
whereas the levels of E2 remained higher than controls
(Fig. 2A and B).Effect of hyperandrogenism and metformin on ovarian
oxidative stress
In ovarian tissue with functional CL, none of the
treatments were able to modify ovarian LPO (Fig. 3A).
Hyperandrogenization with DHEA increased SOD
activity when compared to the control group (Fig. 3B).
Metformin alone or administered together with DHEA
increased SOD activity when compared to the control
group (Fig. 3B) and none of the treatments were able to
modify CAT activity (Fig. 3C).
In ovarian tissue with regressing CL, both metformin
alone and DHEA decreased ovarian LPO when
compared to controls (Fig. 4A). However, when
metformin was administered together with DHEA, the
ovarian LPO levels did not differ from that of controls
(Fig. 4A). DHEA increased both SOD and CAT activitieswww.reproduction-online.org
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Figure 2 (A) Serum progesterone levels from mice with ovaries with
regressing corpora lutea treated with vehicle (control), metformin,
DHEA, and DHEACmetformin. (B) Serum estradiol levels from mice
with ovaries with regressing corpora lutea treated with metformin,
DHEA, and DHEACmetformin. Each column represents the mean
GS.E.M. of ten measurements from different animals, *,**P!0.001.
Figure 3 (A) Lipid peroxidation of ovarian tissue with functional corpora
lutea from mice treated with vehicle (control), metformin, DHEA, and
DHEACmetformin. (B) Ovarian superoxide dismutase activity of
ovarian tissue with functional corpora lutea from mice treated with
vehicle (control), metformin, DHEA, and DHEACmetformin.
*P!0.05; **P!0.001. (C) Ovarian catalase activity of ovarian tissue
with functional corpora lutea from mice treated with metformin,
DHEA, and DHEACmetformin. Each column represents the mean
GS.E.M. of ten measurements from different animals.
DHEA and metformin in CL 573when compared to the control group (Fig. 4B and C), and
metformin alone increased CAT activity but not SOD
activity (Fig. 4C). When metformin was administered
together with DHEA, SOD activity remained higher than
that of controls, whereas CAT activity was similar to that
of control values (Fig. 4B and C).
Effect of hyperandrogenism and metformin in ovarian
%OH scavenging
5,5-dimethyl-1-pyrroline N-oxide (DMPO)/%OH adduct
was increased by all the treatments in ovarian tissue with
functional CL (Fig. 5A and E–H). These data revealed that
DHEA decreased the capacity to scavenge %OH and that
metformin was not able to prevent the effect of DHEA in
ovaries with functional CL.
In contrast with ovarian tissue with functional CL, in
ovarian tissue with regressing CL, the electron spin
resonance (ESR) signal intensity of the DMPO/%OH
adduct corresponding to both the metformin alone and
DHEAgroupwasdecreasedwhencompared to the control
group (Fig. 5B and I–K). These data revealed that DHEA
increased the capacity to scavenge %OH in ovaries with
regressing CL. Metformin given together with DHEA pre-
vented the actionofDHEAonESR signal (Fig. 5B, I, and L).
In order to address whether DHEA and metformin act
direct or indirectly as ovarian %OH scavenger, we also
assayed the effect of increasing concentrations of DHEA
and metformin in medium free of ovarian homogenates.
We found that neither DHEA nor metformin generated
any change in the signal of the adduct DMPO/%OHwhen
compared to the control reaction (FentonCDMPO) (data
not shown).www.reproduction-online.orgOvarian PGF2a and PGE concentration
We investigated whether the luteolytic prostanoid PGF2a
and the luteotrophic PGE were regulated by DHEA and
metformin. None of the treatments were able to modify
the PGF2a or PGE produced by ovaries with functional
CL (Fig. 6A and B respectively). However, DHEA
decreased PGF2a levels and increased the levels of
ovarian PGE produced by ovaries with regressing CL
(Fig. 6C and D respectively). When metformin was
administered together with DHEA, PGF2a and PGE levels
were similar to controls (Fig. 6C and D respectively).
Discussion
The present study was undertaken to improve our
understanding on the effect of the excess of androgens
and that of metformin treatment in two well-definedReproduction (2009) 138 571–579
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574 V A Sander and othersmetabolic and hormonal states of CL lifespan. We found
a dual effect of hyperandrogenism in modulating Pand E2
synthesis. During the functional stage of CL develop-
ment, DHEA decreased both serum P and E2 levels
(Fig. 1). In agreement with these findings, it has been
reported that women with PCOS show lower levels of P
in the early luteal phase when compared to healthy
controls (Joseph-Horne et al. 2002, Lunn et al. 2002).
Moreover, the inability of women with PCOS to sustain
early pregnancy is correlated to the decrease in ovarian
steroidogenesis during the luteal phase (Franks 1995,
Meenakumari et al. 2004).
Contrary to the functional stage, during the regressing
stage ofCLdevelopment,DHEAenhanced serumPandE2
levels (Fig. 2). According to this finding, it has been
reported that an excess of androgens leads to more
prolonged sexual cycles in PCOS patients by rescuing the
CL from luteolysis (Manikkam et al. 2006). The ability of
DHEA to stimulate E2 secretion has also been previously
reported in human granulose cells (Bonser et al. 2000),
and themechanism proposed is the enhanced expression
of P450 aromatase by DHEA (Elbeltagy et al. 2007).
Moreover, Genazzani et al. (2006) have recently reportedFigure 4 (A) Lipid peroxidation of ovarian tissue with regressing corpora
lutea from mice treated with vehicle (control), metformin, DHEA, and
DHEACmetformin, *P!0.001. (B) Ovarian superoxide dismutase
activity of ovarian tissuewith regressing corpora lutea frommice treated
with vehicle (control), metformin, DHEA, and DHEACmetformin,
*P!0.001 (C) Ovarian catalase activity of ovarian tissue with regressing
corpora lutea from mice treated with vehicle (control), metformin,
DHEA, and DHEACmetformin *P!0.001. Each column represents the
meanGS.E.M. of ten measurements from different animals.
Figure 5 Detection of DMPO/%OH adducts by Fenton reaction of
ovarian tissue with functional corpora luteum. (A) Mean signal
intensities of DMPO/%OH; (C) ESR spectrum of DMPO/%OH adduct
generated by the Fenton reaction alone; (D) simulated ESR spectrum of
3C. Experimental electron spin resonance spectra obtained from
ovarian tissue at functional stage of CL development from the control
group (E), the Metformin group (F), the DHEA group (G), and the
DHEACmetformin group (H). ***P!0.001 versus control group. The
arrows in spectrum 3B indicate the lines corresponding to the hyperfine
splitting of DMPO/%OH adduct. Detection of DMPO/%OH adducts by
Fenton reaction of ovarian tissue with regressing corpora lutea.
(B) Mean signal intensities of DMPO/%OH; experimental electron spin
resonance spectra obtained from ovarian tissue at luteal regression from
the control group (I), the metformin group (J), the DHEA group (K), and
the DHEACmetformin group (L). ***P!0.001 versus control group.
The hyperfine interaction constant values obtained from simulation and
fits were aNZ15.0 Gauss and aHbZ14.
Reproduction (2009) 138 571–579that administration of DHEA in postmenopausal women
is capable of increasing circulating levels of androgens
and progestins.
The dual effect of DHEA in regulating ovarian function
has been reported in our previous studies, where
hyperandrogenization with DHEA was able both to
decrease serum P and E2 levels from early pregnant
mice – state of enhanced steroidogenesis – (Solano et al.
2006) and to increase both steroids from prepuberal
femalemice – state of poor steroidogenesis – (Sander et al.
2006). Comparing these data with the present results, it
appears that DHEA inhibits ovarian steroidogenesis
when it is high in young fully functional CL, but stimulates
it when it is low in CL nearing the end of their lifespan.www.reproduction-online.org
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Figure 6 Effect of DHEA and metformin on (A) prostaglandin F2a and
(B) prostaglandin E from ovaries with functional corpora luteum
(C) prostaglandin F2a and (D) prostaglandin E from ovarieswith regressing
corpora lutea. Each column represents the meanGS.E.M. of three
measurements fromfivepooledovaries fromdifferentanimals, *P!0.001.
DHEA and metformin in CL 575With respect to metformin treatment, we found that
during the functional stage of CL development, metfor-
min given together with DHEA prevented the decrease of
E2 while it did not prevent DHEA-induced decrease on
serum P levels (Fig. 1). Controversial results have been
reported on the action of metformin in modulating
ovarian steroidogenesis during the luteal phase. While
Meenakumari et al. (2004) demonstrated that metformin
restores P levels during the functional stage of CL
development in PCOS patients, Vrbı́ková et al. (2001)
reported no significant changes in basal steroid pro-
duction. Our results are in agreement with those reported
by Tosca et al. (2006b), who found that metformin
increases E2 secretion of no-stimulated granulose cells.
Conversely to that observed in the functional phase, we
found that DHEA increased both serum P and E2 levels
during luteolysis (Fig. 2). The mechanisms by whichwww.reproduction-online.orgmetformin regulates ovarian steroidogenesis remain
unknown. It has been demonstrated that metformin
regulates P synthesis by modulating the phosphorylation
of AMP-activated protein kinase (AMPK; Elia et al. 2006,
Tosca et al. 2006a, 2006b). However, AMPK activation
does not seem to be essential for regulating E2 production
(Tosca et al. 2006b). It has been reported that metformin
regulates E2 levels by decreasing the amount of CYP19A1
protein by an AMPK-independent mechanism (La Marca
et al. 2002, Tosca et al. 2006a, 2006b). Unexpectedly, we
found that metformin alone modified ovarian steroid
synthesis (Figs 1 and 2). In fact, it has been reported that
metformin alone modulates ovarian steroid synthesis in
no-stimulated human leukocytes (Bonnefont-Rousselot
et al. 2003), no-stimulated granulosa cells (Tosca et al.
2006b), and no-stimulated endometriotic stromal cells
(Takemura et al. 2007). However, the mechanisms
involved remain unknownand studies are being designed
to clarify this point.
Considering that ROSmodulate the lifespan of CL (Riley
& Berhman 1991, Sawada & Carlson 1991, Minegishi
et al. 2002), we also quantified the ovarian oxidative
status. As we expected, and like in the case of ovarian
steroidogenesis, we found that both DHEA andmetformin
regulate the balance of ROS according to the endocrine
status. During the functional stage of CL development,
the hyperandrogenization with DHEA and metformin
treatment increased SOD activity (Fig. 3b). Since this
enzyme detoxifies the cells from O,K2 accumulation, it
represents the first pathway to be regulated. The fact that
during the functional stage of CL development all the
treatments increased SOD activity verifies this point
(Fig. 3B). On the other hand, hyperandrogenism and
metformin decreased the capacity of ovarian tissue with
functional CL to scavenge %OH (Fig. 5G and F); however,
LPO was not increased (Fig. 3A), perhaps because the
capacity to scavenge O,K2 – one of the most aggressive
ROS – is higher in ovaries with functional CL than in those
ovaries with regressing CL (Fig. 3B).
Respect to the role of hyperandrogenism prolonging
the lifespan of CL, we found that DHEA decreased
ovarian LPO (Fig. 4A) and increased both the CAT
activity (Fig. 4C) and the capacity of ovarian tissue to
scavenge %OH (Fig. 5K). Metformin treatment was able to
prevent the decrease in LPO by acting on CAT activity
(Fig. 4C) and the capacity to scavenge %OH (Fig. 5L). We
also found that metformin alone was able to decrease
LPO (Fig. 4A) and increase both the CATactivity (Fig. 4C)
and the capacity to scavenge %OH (Fig. 5J). The structure
of biguanides gives the molecules the property of being
highly reactive to interact with ROS (Bonnefont-
Rousselot et al. 2003). For this reason, we suggest that
metformin alone is able to modulate oxidative stress and
to modify ovarian steroidogenesis.
Concurrently with the rescue of CL from luteolysis by
DHEA, we found a decrease in PGF2a production and an
increase in PGE (Fig. 6C and D). These data areReproduction (2009) 138 571–579
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576 V A Sander and othersconsistent with previous findings about the role of PGF2a
in the generation of ROS and the luteotrophic role of
PGE (Riley & Behrman 1991, Sawada & Carlson 1991,
Motta et al. 2001a, Minegishi et al. 2002). Metformin
treatment prevented the effects of DHEA since neither
LPO (Fig. 4A) nor both PGs (Fig. 6) were different from
controls allowing CL to regress.
We conclude that hyperandrogenism acts as a pro-
oxidant agent during the functional stage of CL
development but as anti-oxidant during spontaneous
luteolysis, and our results are in agreement with those
reported in other systems (Bonser et al. 2000). The dual
effect of hyperandrogenism in the balance of ROS
coincides with the dual effect of DHEA in regulating
ovarian steroidogenesis. Regarding the effect of metfor-
min, our findings suggest that metformin prevents the
effects of DHEA mostly through the modulation of ROS
leading to the restoration of PG balance that in turn
normalizes ovarian steroid synthesis and CL lifespan.Materials and Methods
Experimental design
Animals were kept and handled according to the NIH
publication number 86–23 (revised in 1985 and 1991) and the
UK requirements for ethics of animal experimentation (Animal
Scientific Procedures, Act 1986). The studies were approved by
the ‘Independent Committee on Ethics in Research’ of the
School of Medicine of the University of Buenos Aires. The
animal model used has been previously described (Sander et al.
2008). Briefly, immature (25–30 days of age) female BALB/c
mice were i.p. given 10 IU/mouse of pregnant mare’s serum
gonadotropin (Sigma Chemical Co). This treatment leads to
follicular development and ovulation 48 h later (day 0) and
induces mostly the formation of CL that remains functional for
9G1 days. Effects of treatment with DHEA were assessed on
either ovaries with functional CL or regressing CL by two s.c.
injections of 60 mg DHEA/kg body weight (DHEA group), 24 h
apart on days 3 and 4 after ovulation, followed by decapitation
on day 5 (functional CL) or on day 7 and 8, followed by
decapitation on day 9 (regressing CL).
To investigate the action of metformin, two groups of mice at
both stages of CL development received either metformin alone
(metformin group; 50 mg/kg body weight in 0.05 ml of water,
orally) or in combination with the injection of DHEA (DHEAC
metformin group) on day 3 and 4 for mice with ovaries with
functional CL and day 7 and 8 for mice with ovaries with
regressing CL. The dose of DHEA injected was that previously
used by Lee et al. (1991, 1998), Henmi et al. (2001), Luchetti
et al. (2004), Sander et al. (2005, 2006), Elia et al. (2006) and
Solano et al. (2006) and ensure a hyperandrogenized status.
The dose of metformin administered was ensured to that used
in the treatment of women with PCOS.
Control groups were two: in one group, mice were given
vehicle either orally or s.c. A second control group consisted in
mice without treatment. Since no differences were found
between the two control groups, the results of both control
groups were pooled in only one control group.Reproduction (2009) 138 571–579Housing of animals and sample collection
Thirty animals/group of each stage of CL development were
housed under controlled temperature (22 8C) and light (14 h
light:10 h darkness cycles; lights on at 0500 h) and allowed free
access to Purina Rat Chow and water. Animals from the four
groups (control, metformin alone, DHEA alone, and DHEAC
metformin) of each stage were killed by decapitation and trunk
blood was collected. Serum was isolated and stored at K70 8C
until assayed for P and E2. Freshly dissected ovaries (taken from
different animals in all cases) were divided as follows: ten
ovaries per group were immediately collected and processed to
evaluate LPO, ten for SOD, ten for CAT, and ten to quantify total
antioxidant capacity to scavenge %OH. Finally, 20 ovaries per
group were immediately frozen at K70 8C until assayed for
PGF2a and PGE by RIA.Progesterone and E2 RIA
We evaluated serum concentration of P and E2 by specific RIA
as described previously (Luchetti et al. 2004). Both antisera,
which were highly specific, were kindly provided by Dr G D
Niswender (Colorado State University, Fort Collins, CO, USA).
The cross-reactivity of P antiserum was !2.0% for 20
a-dihydroprogesterone and deoxycorticosterone. The cross-
reactivity of E2 antiserum was !1% for P and testosterone,
!5% for 17-a estradiol and estriol, and !10% for estrone.
Since both sensitivities were 5–10 pg/tube, 2–5 ml serum were
routinely assayed. Results are expressed as pg/ml serum.Oxidative stress-related parameters
Lipid peroxidation
The amount of malondialdehyde (MDA), which is formed from
the breakdown of fatty acids, may be taken as an index of LPO.
The method quantifies the amount of MDA that reacts with
trichloroacetic acid–thiobarbituric acid–HCl (15% w/v;
0.375% w/v and 0.25 M respectively), yielding a red
compound that absorbs at 535 nm (Motta et al. 2001a). Single
ovaries were homogenized in 850 ml 0.5% v/v trichloroacetic
acid; 350 ml homogenates were treated with trichloroacetic
acid–thiobarbituric acid–HCl and heated for 15 min in a
boiling water bath. After cooling, the flocculent precipitate was
removed by centrifugation at 1000 g for 10 min. Absorbance of
samples was determined at 535 nm. Content of thiobarbituric
acid reactants is expressed as mmol MDA formed/mg protein.
SOD activity
SODs are a group of metalloenzymes that detoxify ROS
through the conversion of O,K2 to H2O2 and molecular oxygen.
Total SOD activity was assayed by a spectrophotometric
method based on the inhibition of a superoxide-induced
epinephrine oxidation (Misra & Fridovich 1972). O,K2 serves
as chain propagation species for the autoxidation of epi-
nephrine to adrenochrome. SOD competes with this reaction,
thus decelerating the adrenochrome formation. One unit of
SOD is defined as the amount of extract that inhibits the rate of
adrenochrome formation by 50%. Briefly, one ovary per
determination (ten ovaries per group) was homogenizedwww.reproduction-online.org
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DHEA and metformin in CL 577in 50 mM phosphate buffer (pH 7.2) and centrifuged at
800 g for 10 min at 4 8C. Supernatants were collected and
0.05 M carbonate buffer (pH 10.2) containing 0.1 mM EDTA
and followed by 30 mM epinephrine in 0.05% v/v acetic acid
was added. The change in SOD activity was measured at
480 nm for 4 min. The control was made following the same
protocol but samples were replaced by carbonate buffer, pH
10.2. To calculate units of SOD in the samples, it has been
defined that
1 unit ðUÞ of SODZVcontrol=VsampleK1
V is the slope of the change in absorbance in the absence and in
the presence of ovarian homogenates.
CAT activity
The technique used is based on the ability of CAT to catalyse
the conversion of H2O2 to molecular oxygen andwater (Solano
et al. 2006). Briefly, one ovary per determination (ten ovaries
per group) was homogenized as previously described for the
SOD assay. Homogenates (100 ml/point) were incubated with
3 ml of 50 mM phosphate buffer (pH 7.2) and 100 ml of 3 M
H2O2. Since H2O2 absorbs at 240 nm, its consumption was
monitored by a spectrophotometer for 1 min at 10 s intervals.
Results are expressed as pmol/mg protein.
Electron spin resonance assay
Ten ovaries per group were assayed to determine the
antioxidant capacity of the ovarian tissue to scavenge %OH.
Each ovary per determination (ten ovaries per group) was
homogenized in a solution of DMPO 200 mM. Immediately,
FeSO4 (final concentrationZ3 mM) and H2O2 (final concen-
trationZ150 mM) were added in order to generate %OH by a
Fenton reaction (equation 1). The electron spin resonance
spectra of the spin adduct DMPO/(%OH) (equation 2) were
recorded 2 min after the addition of H2O2. Measurements were
obtained at 20 8C using an X-band Electron Spin Resonance
Spectrometer Bruker ECS 106. The spectrometer settings were:
center field 3483 G, sweep width 80 G, microwave power
10 mW, microwave frequency 9.76 GHz, conversion time
2.56 ms, time constant 2.56 ms, modulation frequency
50 KHz, modulation amplitude 0.103 G, gain 2.00!104, and
resolution 1024 points. All spectra were the accumulation of
ten scans. DMPO/%OH signal intensity was measured as the
total height of the low-field peak (hC1) in the first derivative
spectrum of the 14N triplet. Results were interpreted in terms of
total %OH scavenger capacity in the sample, being a higher





In order to discard possible intrinsic effects of DHEA and
metformin to scavenge, %OH controls without ovarian homo-
genates were carried out in a cell-free medium. Metformin was
studied in the following range of concentrations of
0.1–1000 mM, which include the pharmacological metformin
concentration in human plasma (Yuen & Peh 1998) and DHEAwww.reproduction-online.orgwas tested between 0.01 and 1000 mM, in order to include the
mean serum DHEA concentration present in PCOS (Fridstrom
et al. 1999).Prostaglandin RIA
The capacity of the ovaries to synthesize and release PGF2a
and PGE was determined as previously reported (Elia et al.
2006). Briefly, each ovary (five ovaries per group for each
PG) was incubated in Krebs-Ringer bicarbonate with
11.0 mmol/l glucose (pH 7) as external substrate for 1 h in
a Dubnoff metabolic shaker under an atmosphere of 5%
CO2 in 95% O2 at 37 8C. At the end of the incubation
period, the tissue was removed and the solution acidified to
pH 3.0 with 1 M HCl and extracted for PG determination
three times with 1 volume of ethyl acetate. Pooled ethyl
acetate extracts were dried under an atmosphere of N2 and
stored at K20 8C until PG RIA was performed. PGF2a and
PGE were quantified by using the specific rabbit antiserum
from Sigma Chemical Co. Sensitivity was 10 pg/tube and
cross-reactivity was !0.1% with other PGs. Cross-reactivity
was 100% with PGF2a and PGE respectively. Results are
expressed as pg/mg protein.Level of ovarian protein concentrations
Ovarian protein concentration was determined by the Bradford
method (1976).Statistical analysis
Statistical analyses were carried out by using the Instat program
(GraphPAD software, San Diego, CA, USA). One-way ANOVA
followed by Bonferroni multiple comparison test were
performed in order to assess the statistical significance of
differences between means. P!0.05 was considered
significant.Declaration of interest
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